Boehringer Ingelheim USA Corporation

The Global Exosome Market: Size, Forecast, Trials, and Trends, 2024 report details the growing exosome market, highlighting advancements in diagnostics, therapeutics, and cosmetics. Exosomes, extracellular vesicles, are valuable for disease detection, diagnosis, and treatment. The market is expanding with 388 clinical trials underway, and first exosome therapeutics expected by 2029. Key players and technologies are profiled, along with market forecasts through 2030.

AstraZeneca and Daiichi Sankyo shares fell due to mixed results in a late-stage trial for their lung cancer drug Dato-DXd, which showed some patients lived longer but overall results were not statistically significant. The drug is expected to be approved based on overall survival and progression-free survival improvements.

Semaglutide injections reduced overall, cardiovascular, and infection-related deaths by 19%, 15%, and 23% respectively in a study of 17,000 obese and overweight patients with heart disease.

Biologic drugs for asthma can be used during conception, pregnancy, and breastfeeding with shared decision-making. Use should be recorded in registries, and restarting after birth is recommended if halted. Inactivated vaccinations for infants are safe even if mothers received biologics. Concerns remain due to limited clinical trial data, especially for newer biologics like tezepelumab.

OrsoBio raises $67M to advance weight loss drugs; Vor Bio's CRISPR-edited stem cells show success in AML therapy; Boehringer Ingelheim to test eye drug for geographic atrophy; Novartis licenses capsid from Voyager for gene therapy; Vaxcyte raises $1.3B on positive pneumococcal vaccine data.

Boehringer Ingelheim and CDR-Life report positive Phase I results for BI 771716, an antibody fragment targeting geographic atrophy (GA), meeting safety endpoints. The companies plan to initiate Phase II trials in early 2025, aiming to preserve vision in GA patients, a severe form of AMD leading to irreversible vision loss. BI 771716's design allows optimized retinal penetration and efficacy potential.

M.J.D. has consulted, advised, and spoken for Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi, Pfizer, AstraZeneca, Zealand Pharma, Carmot/Roche, and Amgen. She has also received grants from AstraZeneca, Novo Nordisk, Boehringer Ingelheim, Janssen, Sanofi-Aventis, and Eli Lilly. J.G. has no competing interests.

Evernorth Health Services will offer a private-label biosimilar of Stelara (ustekinumab) starting in early 2025, with a price over 80% lower than Stelara's list price. The biosimilar will be available for $0 out of pocket for eligible patients through Accredo, potentially saving individual patients around $4,000 per year. Evernorth has already seen strong interest in its private-label Humira biosimilar, with over 25% of eligible Accredo patients using it.

September 1 marked the beginning of Suicide Prevention Awareness Month. For the veterinary profession, the suicide rate is high. This week on dvm360.com: clinical trials for canine cardiac tumors, a wellbeing guide for healthcare workers, Boehringer Ingelheim's acquisition of Saiba Animal Health, a podcast on suicide awareness, and updates on veterinary practices in Australia.